Lifestyle Drugs Market Vendors Research and Analysis Report to 2021

ReportsnReports.com adds new research report Global Lifestyle Drugs Market 2017-2021. This report covers the present scenario and the growth prospects of the global lifestyle drugs market for 2017-2021. To calculate the market size, the report considers sales of lifestyle drugs in the market.

Inquire for more information at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=917357

The following companies are the key players in the global lifestyle drugs market: Allergan, BMS, Eli Lilly, and Pfizer.

Other Prominent Vendors in the market are: Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience, Anterios, AstraZeneca, Avanir Pharmaceuticals, Avolynt, Celtaxsys, Cerecor, Corcept Therapeutics, Cosmo Pharmaceuticals, CTC Bio, Dermira, Dong-A ST, Euthymics Bioscience, Foamix, Follicum, Forendo Pharma, Futura Medical Developments, Galderma, Hanmi Pharmaceutical, Incyte, Intrepid Therapeutics, Ion Channel Innovations, iX Biopharma, Johnson & Johnson, Legacy Healthcare, LEO Pharma, H. Lundbeck, Luye America Pharmaceuticals, Merck, Minerva Neurosciences, MSI Methylation Sciences, Neuralstem, Novan, Novartis, Novo-Nordisk, Palatin Technologies, Paratek Pharmaceuticals, Photocure, Revance Therapeutics, Rhythm Pharmaceuticals, S1 Biopharma, Sage Therapeutics, Samumed, Sanofi, Sigma-Tau Pharmaceuticals, Strategic Science & Technologies, Sumitomo Dainippon Pharma, Takeda, TetraLogic Pharmaceuticals, TherapeuticsMD, Valeant Pharmaceuticals, VistaGen Therapeutics, VIVUS, XBiotech, Yuhan, and Zafgen.

One trend in the market is the increase in M&A. The market has been witnessing an increase in M&A, which will lead to further consolidation. The vendors are pursuing inorganic growth strategies such as acquisitions and/or partnerships to expand their lifestyle drugs portfolio and to improve their presence in the market. For instance, in August 2015, Allergan completed the acquisition of Naurex. The acquisition enhanced Allergan’s portfolio of depression drugs with the addition of rapastinel, a Phase III-ready molecule that demonstrated rapid and sustained efficacy in multiple Phase II clinical studies in depression. With the patent expires in the market place, vendors are also looking to enhance their portfolio through acquisition of generics.

Purchase directly at http://www.reportsnreports.com/purchase.aspx?name=917357

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

According to the report, one driver in the market is the lifestyle changes. Lifestyle changes such as physical inactivity, stress, consumption of fast foods, and limited intake of water can lead to the development of acne. Research studies report that people who are physically inactive are prone to develop insulin resistance compared with active individuals. Insulin resistance leads to the production of higher levels of sebum in the skin, resulting in acne development. Research studies also put forth that excess insulin can increase the levels of androgens in the body. High levels of androgens also lead to an increased production of sebum in the skin, resulting in acne development.

Global Lifestyle Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Inquire for discount at http://www.reportsnreports.com/contacts/discount.aspx?name=917357

Further, the report states that one challenge in the market is the patent expiries. The market is currently dominated by key drugs, namely Cymbalta by Eli Lilly, Abilify by Bristol Myers Squibb (BMS), Cialis (tadalafil) by Eli Lilly, Staxyn/Levitra (vardenafil) by Bayer, and Viagra (sildenafil citrate) by Pfizer. The depression drugs such as Cymbalta witnessed a patent expiry in 2013. Due to the patent expiry, Cymbalta reported a YoY decline of 36.36% in 2015. Also, Abilify reported a YoY decline of 63.07% in 2015 due to patent expiration in the US and EU. In addition, the erectile dysfunction drugs Viagra (approved in 1998), Cialis (approved in 2003), Staxyn/Levitra (approved in 2003) drugs were approved long back, and their patents are nearing expiration in the next few years.

About Us:  

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.